A Phase 3 interventional study of CP-690,550 and CP-690, 550 in Psoriasis, sponsored by Pfizer. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-13.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing tofacitinib in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. tofacitinib · Arthritis, Psoriatic.
Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, this one is the 7th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 1st registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 10 studies testing tofacitinib in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
29 studies in Arthritis, Psoriatic by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 28 finished, 22 (79%) have results posted.
Among the 29 studies in Arthritis, Psoriatic by Pfizer, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2012, is one of 6 in phase 3, and was the 15th registered.
Pfizer’s Arthritis, Psoriatic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 29 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10 mg BID) after 16 weeks of treatment.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
This study's enrollment of 95 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
[Moderate to Severe Plaque Psoriasis]
[Psoriatic Arthritis]
Exclusion Criteria:
Drug: CP-690,550
Drug: CP-690, 550
10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.
Time frame: Week 16
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
Time frame: Week 16
Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Week 16
Number of Participants With Adjudicated Cardiovacular Events
Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.
Time frame: Baseline to Follow-up
Number of Participants With Malignancy Events _Week 0 Through Follow-up
For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.
Time frame: Baseline to Follow-up
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.
Time frame: Week 2, 4, 8, 12, 20, 28, 40, 52
Percentage of Participants With a Psoriasis Area and Severity Index 50 (PASI50) Response
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
Time frame: Week 16
Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
Time frame: Week 16
Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
Time frame: Week 16
Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
Time frame: Week 16
Percentage of Participants With a Psoriasis Area and Severity Index (PASI) Score >= 125 Percent of the Baseline PASI Score
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Score
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
Time frame: Week 2, 4, 8, 12, 20, 28, 40, 52
Percentage of Participants in a Physician Global Assessment (PGA) of Psoriasis Score Category
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Percentage of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI75) Response After Week 16
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.
Time frame: Week 20, 28, 40, 52
Percentage of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.
Time frame: Week 20, 28, 40, 52
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.
Time frame: Week 8, 16, 20, 28, 40, 52
Number of Affected Nails
Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.
Time frame: Baseline, Week 8, 16, 20, 28, 40, 52
Itch Severity Item (ISI) Score
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Dermatology Life Quality Index (DLQI) Score
The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Domain Score
36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).
Time frame: Week (W) 16, 28, 52
Change From Baseline in 36-Item Short-Form Health Survey Version 2, Acute (SF-36): Component Summary Score
36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).
Time frame: Week 16, 28, 52
Work Limitation Questionnaire (WLQ)
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).
Time frame: Baseline (BL), Week (W) 4, 16, 28, 52
Percentage of Participants With a Patient Global Assessment (PtGA) of Psoriasis Score Category
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Joint Pain Assessment (JPA)
The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to "select the number that best describes any joint pain that participant may have experienced over the past 24 hours" with response options ranging from "0-no joint pain" to "10-worst possible joint pain."
Time frame: Baseline, Week 4, 16, 28, 52
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Week 2, 4, 8, 12, 20, 28, 40, 52
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
ACR50 response: greater than or equal to (\>=) 50 percent (%) improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
ACR70 response: greater than or equal to (\>=) 70 percent (%) improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in American College of Rheumatology (ACR) Component_ Tender/Painful Joint Count
Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in American College of Rheumatology (ACR) Component_ Swollen Joint Count
Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Assessment of Arthritis Pain
Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in American College of Rheumatology (ACR) Component_ Patient Global Assessment of Arthritis
Subjects answered the following question, "Considering the possible effects of the arthritis, how are you feeling today?" The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in American College of Rheumatology (ACR) Component_ Physician Global Assessment of Arthritis
The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in American College of Rheumatology (ACR) Component_ C-Reactive Protein (CRP)
The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Change From Baseline in American College of Rheumatology (ACR) Component_ Health Assessment Questionnaire - Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
| Milestone | CP-690,550 5 mg BID | CP-690,550 10 mg BID |
|---|---|---|
| Started | 47 | 48 |
| Received treatment | 47 | 47 |
| Completed | 40 | 33 |
| Not completed | 7 | 15 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Other | 2 | 6 |
| Withdrew: Not received study drug | 0 | 1 |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at Week 16 relative to Baseline.
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16 | 62.8 | 72.7 | 67.8 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Percentage of Participants With a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 | 67.4 | 68.2 | 67.8 |
ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Proportion of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 | 100 | 100 | 100 |
Adjudicated cardiovascular events were assessed by investigators as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; specific requirements vary with the event requiring adjudication.
| Participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Number of Participants With Adjudicated Cardiovacular Events | 0 | 0 | 0 |
For all biopsies of potentially malignant tumors, suspicious lymphadenopathy, or possible extranodal LPD, the study site requested the pathologist to send the original slides used to make the definitive diagnosis, ancillary study reports, and the pathologist's report to the central laboratory for a blinded review by a central pathologist.
| Participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Number of participants with any malignancy events | 0 | 0 | 0 |
| Malignancy excluding non-melanoma skin cancer | 0 | 0 | 0 |
| Lymphoma/Lymphoproliferative disorders (LPD) | 0 | 0 | 0 |
| Melanoma | 0 | 0 | 0 |
| Non-melanoma skin cancer | 0 | 0 | 0 |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI at the each visit relative to Baseline.
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 2.3 | 4.5 | 3.4 |
| Week 4 | 7.0 | 22.7 | 14.9 |
| Week 8 | 41.9 | 54.5 | 48.3 |
| Week 12 | 60.5 | 70.5 | 65.5 |
| Week 20 | 67.4 | 63.6 | 65.5 |
| Week 28 | 69.8 | 65.9 | 67.8 |
| Week 40 | 69.8 | 63.6 | 66.7 |
| Week 52 | 62.8 | 63.6 | 63.2 |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least a 50 percent (%) reduction in PASI at the each visit relative to Baseline.
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 9.3 | 22.7 | 16.1 |
| Week 4 | 34.9 | 56.8 | 46.0 |
| Week 8 | 60.5 | 81.8 | 71.3 |
| Week 12 | 81.4 | 84.1 | 82.8 |
| Week 16 | 76.7 | 79.5 | 78.2 |
| Week 20 | 79.1 | 75.0 | 77.0 |
| Week 28 | 90.7 | 72.7 | 81.6 |
| Week 40 | 88.4 | 79.5 | 83.9 |
| Week 52 | 90.7 | 68.2 | 79.3 |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90 percent (%) reduction in PASI at the each visit relative to Baseline.
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 0.0 | 0.0 | 0.0 |
| Week 4 | 4.7 | 13.6 | 9.2 |
| Week 8 | 16.3 | 29.5 | 23.0 |
| Week 12 | 37.2 | 45.5 | 41.4 |
| Week 16 | 37.2 | 54.5 | 46.0 |
| Week 20 | 58.1 | 56.8 | 57.5 |
| Week 28 | 55.8 | 45.5 | 50.6 |
| Week 40 | 58.1 | 47.7 | 52.9 |
| Week 52 | 51.2 | 47.7 | 49.4 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
| Week | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | 8.0 (8.0 to 12.0) | 8.0 (4.0 to 12.0) | 8.0 (NA to NA) |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
| Week | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Time to Achieve a Psoriasis Area and Severity Index 75 (PASI75) Response | 12.0 (8.0 to 16.0) | 8.0 (8.0 to 12.0) | 12.0 (8.0 to 12.0) |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
| Week | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Time to Achieve a Psoriasis Area and Severity Index 50 (PASI50) Response | 8.0 (4.0 to 12.0) | 4.0 (4.0 to 8.0) | 8.0 (4.0 to 8.0) |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and "percent of BSA" affected. PASI is a composite scoring assessed by the investigator, of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least 90% reduction in PASI relative to Baseline. The median time to event is estimated based on Kaplan-Meier product-limit method. Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
| Week | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Time to Achieve a Psoriasis Area and Severity Index 90 (PASI90) Response | NA (12.0 to NA) | 12.0 (12.0 to 16.0) | 16.0 (12.0 to NA) |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 2.3 | 0.0 | 1.1 |
| Week 4 | 0.0 | 2.3 | 1.1 |
| Week 8 (n=43, 41, 84) | 0.0 | 0.0 | 0.0 |
| Week 12 (n=43, 41, 84) | 0.0 | 2.4 | 1.2 |
| Week 16 (n=43, 40, 83) | 0.0 | 2.5 | 1.2 |
| Week 20 (n=43, 39, 82) | 0.0 | 0.0 | 0.0 |
| Week 28 (n=43, 39, 82) | 0.0 | 0.0 | 0.0 |
| Week 40 (n=41, 38, 79) | 0.0 | 0.0 | 0.0 |
| Week 52 (n=39, 32, 71) | 0.0 | 0.0 | 0.0 |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -5.18 ± 5.898 | -7.36 ± 6.428 | -6.28 ± 6.232 |
| Week 4 | -10.40 ± 7.518 | -13.16 ± 8.739 | -11.79 ± 8.229 |
| Week 8 (n=43, 41, 84) | -15.95 ± 8.392 | -19.90 ± 10.741 | -17.88 ± 9.756 |
| Week 12 (n=43, 41, 84) | -18.91 ± 8.918 | -21.68 ± 11.598 | -20.26 ± 10.344 |
| Week 16 (n=43, 40, 83) | -19.53 ± 9.094 | -22.06 ± 12.606 | -20.75 ± 10.935 |
| Week 20 (n=43, 39, 82) | -20.95 ± 9.239 | -22.18 ± 12.045 | -21.53 ± 10.617 |
| Week 28 (n=43, 39, 82) | -21.77 ± 10.196 | -21.46 ± 10.503 | -21.62 ± 10.280 |
| Week 40 (n=41, 38, 79) | -22.20 ± 10.181 | -21.18 ± 10.229 | -21.71 ± 10.151 |
| Week 52 (n=39, 32, 71) | -21.96 ± 9.621 | -22.11 ± 10.598 | -22.03 ± 10.000 |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2: Erythema (Head/Neck) | -0.5 ± 0.83 | -0.9 ± 0.82 | -0.7 ± 0.84 |
| Week 2: Erythema (Upper Limbs) | -0.5 ± 0.67 | -0.8 ± 0.72 | -0.6 ± 0.70 |
| Week 2: Erythema (Trunk) | -0.6 ± 0.67 | -0.8 ± 0.69 | -0.7 ± 0.69 |
| Week 2: Erythema (Lower Limbs) | -0.7 ± 0.69 | -0.8 ± 0.71 | -0.7 ± 0.70 |
| Week 2: Induration (Head/Neck) | -0.4 ± 0.70 | -0.8 ± 0.89 | -0.6 ± 0.82 |
| Week 2: Induration (Upper Limbs) | -0.5 ± 0.63 | -0.6 ± 0.75 | -0.6 ± 0.69 |
| Week 2: Induration (Trunk) | -0.5 ± 0.63 | -0.7 ± 0.59 | -0.6 ± 0.62 |
| Week 2: Induration (Lower Limbs) | -0.5 ± 0.67 | -0.7 ± 0.71 | -0.6 ± 0.69 |
| Week 2: Scaling (Head/Neck) | -0.4 ± 0.66 | -0.9 ± 0.91 | -0.7 ± 0.83 |
| Week 2: Scaling (Upper Limbs) | -0.4 ± 0.59 | -0.8 ± 0.74 | -0.6 ± 0.69 |
| Week 2: Scaling (Trunk) | -0.3 ± 0.57 | -0.8 ± 0.76 | -0.6 ± 0.71 |
| Week 2: Scaling (Lower Limbs) | -0.4 ± 0.70 | -0.7 ± 0.73 | -0.6 ± 0.73 |
| Week 4: Erythema (Head/Neck) | -0.8 ± 1.02 | -1.3 ± 0.99 | -1.0 ± 1.02 |
| Week 4: Erythema (Upper Limbs) | -1.1 ± 0.81 | -1.2 ± 0.94 | -1.1 ± 0.87 |
| Week 4: Erythema (Trunk) | -1.0 ± 0.64 | -1.3 ± 0.79 | -1.1 ± 0.72 |
| Week 4: Erythema (Lower Limbs) | -1.1 ± 0.91 | -1.2 ± 0.79 | -1.2 ± 0.85 |
| Week 4: Induration (Head/Neck) | -0.7 ± 0.89 | -1.2 ± 1.09 | -1.0 ± 1.02 |
| Week 4: Induration (Upper Limbs) | -1.1 ± 0.86 | -1.0 ± 0.85 | -1.0 ± 0.85 |
| Week 4: Induration (Trunk) | -0.9 ± 0.80 | -1.3 ± 0.82 | -1.1 ± 0.83 |
| Week 4: Induration (Lower Limbs) | -1.0 ± 0.90 | -1.2 ± 0.98 | -1.1 ± 0.94 |
| Week 4: Scaling (Head/Neck) | -0.8 ± 0.86 | -1.2 ± 0.99 | -1.0 ± 0.95 |
| Week 4: Scaling (Upper Limbs) | -0.9 ± 0.70 | -1.2 ± 0.86 | -1.0 ± 0.79 |
| Week 4: Scaling (Trunk) | -0.9 ± 0.71 | -1.3 ± 0.95 | -1.1 ± 0.87 |
| Week 4: Scaling (Lower Limbs) | -0.8 ± 0.72 | -1.3 ± 0.96 | -1.1 ± 0.89 |
| Week 8: Erythema (Head/Neck) (n=43, 41, 84) | -1.4 ± 1.13 | -1.6 ± 1.03 | -1.5 ± 1.08 |
| Week 8: Erythema (Upper Limbs) (n=43, 41, 84) | -1.5 ± 0.93 | -1.6 ± 0.98 | -1.5 ± 0.95 |
| Week 8: Erythema (Trunk) (n=43, 41, 84) | -1.7 ± 0.91 | -1.9 ± 0.93 | -1.8 ± 0.92 |
| Week 8: Erythema (Lower Limbs) (n=43, 41, 84) | -1.5 ± 0.91 | -1.7 ± 0.91 | -1.6 ± 0.91 |
| Week 8: Induration (Head/Neck) (n=43, 41, 84) | -1.3 ± 0.91 | -1.6 ± 1.10 | -1.4 ± 1.01 |
| Week 8: Induration (Upper Limbs) (n=43, 41, 84) | -1.6 ± 0.93 | -1.6 ± 0.89 | -1.6 ± 0.91 |
| Week 8: Induration (Trunk) (n=43, 41, 84) | -1.6 ± 0.98 | -1.7 ± 1.03 | -1.7 ± 1.00 |
| Week 8: Induration (Lower Limbs) (n=43, 41, 84) | -1.6 ± 0.91 | -1.7 ± 0.98 | -1.7 ± 0.94 |
| Week 8: Scaling (Head/Neck) (n=43, 41, 84) | -1.3 ± 0.90 | -1.5 ± 1.03 | -1.4 ± 0.96 |
| Week 8: Scaling (Upper Limbs) (n=43, 41, 84) | -1.3 ± 0.80 | -1.6 ± 0.86 | -1.5 ± 0.84 |
| Week 8: Scaling (Trunk) (n=43, 41, 84) | -1.4 ± 0.82 | -1.8 ± 1.00 | -1.6 ± 0.93 |
| Week 8: Scaling (Lower Limbs) (n=43, 41, 84) | -1.3 ± 0.82 | -1.8 ± 0.88 | -1.5 ± 0.88 |
| Week 12: Erythema (Head/Neck) (n=43, 41, 84) | -1.7 ± 1.10 | -1.7 ± 0.98 | -1.7 ± 1.04 |
| Week 12: Erythema (Upper Limbs) (n=43, 41, 84) | -1.9 ± 0.99 | -1.8 ± 1.13 | -1.8 ± 1.05 |
| Week 12: Erythema (Trunk) (n=43, 41, 84) | -2.1 ± 1.08 | -2.0 ± 0.95 | -2.0 ± 1.01 |
| Week 12: Erythema (Lower Limbs) (n=43, 41, 84) | -1.9 ± 0.92 | -1.9 ± 0.94 | -1.9 ± 0.92 |
| Week 12: Induration (Head/Neck) (n=43, 41, 84) | -1.5 ± 0.94 | -1.6 ± 1.12 | -1.6 ± 1.02 |
| Week 12: Induration (Upper Limbs) (n=43, 41, 84) | -1.7 ± 0.94 | -1.8 ± 0.99 | -1.7 ± 0.96 |
| Week 12: Induration (Trunk) (n=43, 41, 84) | -2.0 ± 1.01 | -2.0 ± 1.00 | -2.0 ± 1.00 |
| Week 12: Induration (Lower Limbs) (n=43, 41, 84) | -1.9 ± 0.91 | -1.9 ± 1.06 | -1.9 ± 0.98 |
| Week 12: Scaling (Head/Neck) (n=43, 41, 84) | -1.7 ± 0.92 | -1.6 ± 1.02 | -1.6 ± 0.96 |
| Week 12: Scaling (Upper Limbs) (n=43, 41, 84) | -1.4 ± 0.91 | -1.7 ± 0.95 | -1.6 ± 0.94 |
| Week 12: Scaling (Trunk) (n=43, 41, 84) | -1.6 ± 1.05 | -1.9 ± 1.00 | -1.7 ± 1.03 |
| Week 12: Scaling (Lower Limbs) (n=43, 41, 84) | -1.5 ± 0.85 | -1.9 ± 1.00 | -1.7 ± 0.95 |
| Week 16: Erythema (Head/Neck) (n=43, 40, 83) | -1.7 ± 1.14 | -1.7 ± 1.07 | -1.7 ± 1.10 |
| Week 16: Erythema (Upper Limbs) (n=43, 40, 83) | -1.9 ± 1.13 | -1.9 ± 1.12 | -1.9 ± 1.12 |
| Week 16: Erythema (Trunk) (n=43, 40, 83) | -2.1 ± 1.10 | -2.0 ± 1.07 | -2.0 ± 1.08 |
| Week 16: Erythema (Lower Limbs) (n=43, 40, 83) | -2.0 ± 1.03 | -1.9 ± 0.94 | -2.0 ± 0.99 |
| Week 16: Induration (Head/Neck) (n=43, 40, 83) | -1.5 ± 0.96 | -1.6 ± 1.17 | -1.6 ± 1.06 |
| Week 16: Induration (Upper Limbs) (n=43, 40, 83) | -1.8 ± 0.96 | -1.8 ± 1.01 | -1.8 ± 0.98 |
| Week 16: Induration (Trunk) (n=43, 40, 83) | -2.1 ± 1.01 | -2.0 ± 1.01 | -2.0 ± 1.01 |
| Week 16: Induration (Lower Limbs) (n=43, 40, 83) | -2.1 ± 0.95 | -2.0 ± 1.08 | -2.0 ± 1.01 |
| Week 16: Scaling (Head/Neck) (n=43, 40, 83) | -1.6 ± 0.95 | -1.6 ± 1.08 | -1.6 ± 1.01 |
| Week 16: Scaling (Upper Limbs) (n=43, 40, 83) | -1.5 ± 0.93 | -1.7 ± 1.05 | -1.6 ± 0.99 |
| Week 16: Scaling (Trunk) (n=43, 40, 83) | -1.6 ± 0.96 | -1.8 ± 1.09 | -1.7 ± 1.02 |
| Week 16: Scaling (Lower Limbs) (n=43, 40, 83) | -1.6 ± 0.93 | -1.8 ± 1.06 | -1.7 ± 1.00 |
| Week 20: Erythema (Head/Neck) (n=43, 39, 82) | -1.8 ± 1.15 | -1.6 ± 0.96 | -1.7 ± 1.07 |
| Week 20: Erythema (Upper Limbs) (n=43, 39, 82) | -1.9 ± 0.97 | -1.9 ± 1.26 | -1.9 ± 1.11 |
| Week 20: Erythema (Trunk) (n=43, 39, 82) | -2.2 ± 1.04 | -2.1 ± 1.04 | -2.1 ± 1.04 |
| Week 20: Erythema (Lower Limbs) (n=43, 39, 82) | -2.1 ± 1.04 | -2.1 ± 1.09 | -2.1 ± 1.05 |
| Week 20: Induration (Head/Neck) (n=43, 39, 82) | -1.6 ± 1.00 | -1.5 ± 1.12 | -1.6 ± 1.06 |
| Week 20: Induration (Upper Limbs) (n=43, 39, 82) | -1.9 ± 0.97 | -1.7 ± 1.14 | -1.8 ± 1.05 |
| Week 20: Induration (Trunk) (n=43, 39, 82) | -2.1 ± 1.01 | -1.9 ± 1.07 | -2.0 ± 1.04 |
| Week 20: Induration (Lower Limbs) (n=43, 39, 82) | -2.2 ± 0.95 | -2.0 ± 1.06 | -2.1 ± 1.00 |
| Week 20: Scaling (Head/Neck) (n=43, 39, 82) | -1.7 ± 0.94 | -1.5 ± 1.05 | -1.6 ± 0.99 |
| Week 20: Scaling (Upper Limbs) (n=43, 39, 82) | -1.5 ± 0.96 | -1.6 ± 1.14 | -1.5 ± 1.04 |
| Week 20: Scaling (Trunk) (n=43, 39, 82) | -1.7 ± 0.93 | -1.8 ± 1.05 | -1.8 ± 0.99 |
| Week 20: Scaling (Lower Limbs) (n=43, 39, 82) | -1.7 ± 0.92 | -1.8 ± 1.16 | -1.8 ± 1.04 |
| Week 28: Erythema (Head/Neck) (n=43, 39, 82) | -1.8 ± 1.11 | -1.6 ± 0.81 | -1.7 ± 0.98 |
| Week 28: Erythema (Upper Limbs) (n=43, 39, 82) | -2.1 ± 1.09 | -1.8 ± 1.07 | -2.0 ± 1.08 |
| Week 28: Erythema (Trunk) (n=43, 39, 82) | -2.1 ± 1.13 | -2.0 ± 0.99 | -2.1 ± 1.06 |
| Week 28: Erythema (Lower Limbs) (n=43, 39, 82) | -2.3 ± 1.05 | -1.9 ± 0.99 | -2.1 ± 1.03 |
| Week 28: Induration (Head/Neck) (n=43, 39, 82) | -1.7 ± 0.97 | -1.6 ± 0.99 | -1.6 ± 0.98 |
| Week 28: Induration (Upper Limbs) (n=43, 39, 82) | -2.0 ± 1.12 | -1.7 ± 1.10 | -1.9 ± 1.12 |
| Week 28: Induration (Trunk) (n=43, 39, 82) | -2.0 ± 1.12 | -1.8 ± 1.16 | -1.9 ± 1.14 |
| Week 28: Induration (Lower Limbs) (n=43, 39, 82) | -2.2 ± 1.03 | -1.8 ± 1.14 | -2.0 ± 1.09 |
| Week 28: Scaling (Head/Neck) (n=43, 39, 82) | -1.7 ± 1.01 | -1.4 ± 1.07 | -1.6 ± 1.04 |
| Week 28: Scaling (Upper Limbs) (n=43, 39, 82) | -1.8 ± 1.05 | -1.6 ± 1.02 | -1.7 ± 1.03 |
| Week 28: Scaling (Trunk) (n=43, 39, 82) | -1.7 ± 0.99 | -1.8 ± 1.11 | -1.7 ± 1.05 |
| Week 28: Scaling (Lower Limbs) (n=43, 39, 82) | -1.8 ± 1.09 | -1.7 ± 1.02 | -1.7 ± 1.05 |
| Week 40: Erythema (Head/Neck) (n=41, 38, 79) | -1.9 ± 1.10 | -1.7 ± 0.90 | -1.8 ± 1.01 |
| Week 40: Erythema (Upper Limbs) (n=41, 38, 79) | -2.1 ± 1.05 | -1.9 ± 1.06 | -2.0 ± 1.06 |
| Week 40: Erythema (Trunk) (n=41, 38, 79) | -2.1 ± 1.04 | -2.2 ± 0.87 | -2.2 ± 0.95 |
| Week 40: Erythema (Lower Limbs) (n=41, 38, 79) | -2.4 ± 1.05 | -2.0 ± 1.03 | -2.2 ± 1.05 |
| Week 40: Induration (Head/Neck) (n=41, 38, 79) | -1.7 ± 1.05 | -1.5 ± 1.08 | -1.6 ± 1.07 |
| Week 40: Induration (Upper Limbs) (n=41, 38, 79) | -2.0 ± 1.18 | -1.8 ± 0.98 | -1.9 ± 1.09 |
| Week 40: Induration (Trunk) (n=41, 38, 79) | -1.9 ± 1.26 | -2.1 ± 0.93 | -2.1 ± 1.11 |
| Week 40: Induration (Lower Limbs) (n=41, 38, 79) | -2.2 ± 1.14 | -1.9 ± 1.03 | -2.1 ± 1.10 |
| Week 40: Scaling (Head/Neck) (n=41, 38, 79) | -1.8 ± 0.97 | -1.4 ± 1.00 | -1.6 ± 0.99 |
| Week 40: Scaling (Upper Limbs) (n=41, 38, 79) | -1.7 ± 1.10 | -1.8 ± 0.94 | -1.7 ± 1.02 |
| Week 40: Scaling (Trunk) (n=41, 38, 79) | -1.7 ± 0.93 | -1.9 ± 1.03 | -1.8 ± 0.98 |
| Week 40: Scaling (Lower Limbs) (n=41, 38, 79) | -1.9 ± 1.11 | -1.8 ± 1.06 | -1.8 ± 1.08 |
| Week 52: Erythema (Head/Neck) (n=39, 32, 71) | -1.9 ± 1.17 | -1.6 ± 1.24 | -1.8 ± 1.20 |
| Week 52: Erythema (Upper Limbs) (n=39, 32, 71) | -2.0 ± 1.15 | -2.0 ± 0.90 | -2.0 ± 1.04 |
| Week 52: Erythema (Trunk) (n=39, 32, 71) | -2.2 ± 1.01 | -2.2 ± 0.93 | -2.2 ± 0.97 |
| Week 52: Erythema (Lower Limbs) (n=39, 32, 71) | -2.1 ± 1.11 | -2.2 ± 0.94 | -2.1 ± 1.03 |
| Week 52: Induration (Head/Neck) (n=39, 32, 71) | -1.7 ± 1.06 | -1.5 ± 1.22 | -1.6 ± 1.13 |
| Week 52: Induration (Upper Limbs) (n=39, 32, 71) | -1.9 ± 1.21 | -2.0 ± 0.97 | -1.9 ± 1.10 |
| Week 52: Induration (Trunk) (n=39, 32, 71) | -1.8 ± 1.39 | -2.1 ± 1.03 | -2.0 ± 1.24 |
| Week 52: Induration (Lower Limbs) (n=39, 32, 71) | -2.0 ± 1.29 | -2.2 ± 0.97 | -2.1 ± 1.15 |
| Week 52: Scaling (Head/Neck) (n=39, 32, 71) | -1.8 ± 0.98 | -1.6 ± 1.08 | -1.7 ± 1.02 |
| Week 52: Scaling (Upper Limbs) (n=39, 32, 71) | -1.6 ± 1.02 | -1.9 ± 0.98 | -1.7 ± 1.01 |
| Week 52: Scaling (Trunk) (n=39, 32, 71) | -1.6 ± 0.96 | -1.9 ± 1.01 | -1.7 ± 0.98 |
| Week 52: Scaling (Lower Limbs) (n=39, 32, 71) | -1.7 ± 1.15 | -2.0 ± 1.03 | -1.8 ± 1.10 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 7.0 | 15.9 | 11.5 |
| Week 4 | 30.2 | 38.6 | 34.5 |
| Week 8 | 58.1 | 61.4 | 59.8 |
| Week 12 | 72.1 | 75.0 | 73.6 |
| Week 20 | 72.1 | 59.1 | 65.5 |
| Week 28 | 67.4 | 54.5 | 60.9 |
| Week 40 | 67.4 | 54.5 | 60.9 |
| Week 52 | 58.1 | 56.8 | 57.5 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2: Clear | 0 | 0 | 0 |
| Week 2: Almost Clear | 7.0 | 15.9 | 11.5 |
| Week 2: Mild | 39.5 | 43.2 | 41.4 |
| Week 2: Moderate | 46.5 | 34.1 | 40.2 |
| Week 2: Severe | 7.0 | 6.8 | 6.9 |
| Week 4: Clear | 0 | 11.4 | 5.7 |
| Week 4: Almost Clear | 30.2 | 27.3 | 28.7 |
| Week 4: Mild | 44.2 | 40.9 | 42.5 |
| Week 4: Moderate | 18.6 | 20.5 | 19.5 |
| Week 4: Severe | 7.0 | 0 | 3.4 |
| Week 8: Clear (n=43, 41, 84) | 7.0 | 26.8 | 16.7 |
| Week 8: Almost Clear (n=43, 41, 84) | 51.2 | 39.0 | 45.2 |
| Week 8: Mild (n=43, 41, 84) | 27.9 | 24.4 | 26.2 |
| Week 8: Moderate (n=43, 41, 84) | 14.0 | 9.8 | 11.9 |
| Week 8: Severe (n=43, 41, 84) | 0 | 0 | 0 |
| Week 12: Clear (n=43, 41, 84) | 14.0 | 36.6 | 25.0 |
| Week 12: Almost Clear (n=43, 41, 84) | 58.1 | 43.9 | 51.2 |
| Week 12: Mild (n=43, 41, 84) | 20.9 | 9.8 | 15.5 |
| Week 12: Moderate (n=43, 41, 84) | 7.0 | 9.8 | 8.3 |
| Week 12: Severe (n=43, 41, 84) | 0 | 0 | 0 |
| Week 16: Clear (n=43, 40, 83) | 27.9 | 40.0 | 33.7 |
| Week 16: Almost Clear (n=43, 40, 83) | 39.5 | 35.0 | 37.3 |
| Week 16: Mild (n=43, 40, 83) | 25.6 | 17.5 | 21.7 |
| Week 16: Moderate (n=43, 40, 83) | 7.0 | 5.0 | 6.0 |
| Week 16: Severe (n=43, 40, 83) | 0 | 2.5 | 1.2 |
| Week 20: Clear (n=43, 39, 82) | 27.9 | 38.5 | 32.9 |
| Week 20: Almost Clear (n=43, 39, 82) | 44.2 | 28.2 | 36.6 |
| Week 20: Mild (n=43, 39, 82) | 18.6 | 25.6 | 22.0 |
| Week 20: Moderate (n=43, 39, 82) | 9.3 | 7.7 | 8.5 |
| Week 20: Severe(n=43, 39, 82) | 0 | 0 | 0 |
| Week 28: Clear (n=43, 39, 82) | 37.2 | 33.3 | 35.4 |
| Week 28: Almost Clear (n=43, 39, 82) | 30.2 | 28.2 | 29.3 |
| Week 28: Mild (n=43, 39, 82) | 27.9 | 30.8 | 29.3 |
| Week 28: Moderate (n=43, 39, 82) | 4.7 | 7.7 | 6.1 |
| Week 28: Severe (n=43, 39, 82) | 0 | 0 | 0 |
| Week 40: Clear (n=41, 38, 79) | 43.9 | 34.2 | 39.2 |
| Week 40: Almost Clear (n=41, 38, 79) | 26.8 | 28.9 | 27.8 |
| Week 40: Mild (n=41, 38, 79) | 24.4 | 28.9 | 26.6 |
| Week 40: Moderate (n=41, 38, 79) | 4.9 | 7.9 | 6.3 |
| Week 40: Severe (n=41, 38, 79) | 0 | 0 | 0 |
| Week 52: Clear (n=39, 32, 71) | 41.0 | 43.8 | 42.3 |
| Week 52: Almost Clear (n=39, 32, 71) | 23.1 | 34.4 | 28.2 |
| Week 52: Mild (n=39, 32, 71) | 30.8 | 18.8 | 25.4 |
| Week 52: Moderate (n=39, 32, 71) | 5.1 | 3.1 | 4.2 |
| Week 52: Severe (n=39, 32, 71) | 0 | 0 | 0 |
The PASI quantifies the severity of a participant's psoriasis based on both, "lesion severity" and the "percent of body surface area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among participants achieving PASI75 response at Week 16 is reported.
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 20 | 96.3 | 87.5 | 91.5 |
| Week 28 | 92.6 | 78.1 | 84.7 |
| Week 40 | 81.5 | 71.9 | 76.3 |
| Week 52 | 70.4 | 62.5 | 66.1 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported.
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 20 | 100 | 83.3 | 91.5 |
| Week 28 | 93.1 | 73.3 | 83.1 |
| Week 40 | 82.8 | 66.7 | 74.6 |
| Week 52 | 65.5 | 60.0 | 62.7 |
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 8 (n=32, 28, 60) | -3.3 ± 9.63 | -1.8 ± 7.72 | -2.6 ± 8.75 |
| Week 16 (n=32, 28, 60) | -11.2 ± 15.27 | -9.4 ± 12.66 | -10.4 ± 14.02 |
| Week 20 (n=32, 27, 59) | -15.0 ± 15.29 | -14.1 ± 13.03 | -14.6 ± 14.18 |
| Week 28 (n=32, 27, 59) | -21.1 ± 15.83 | -16.4 ± 15.27 | -18.9 ± 15.62 |
| Week 40 (n=31, 26, 57) | -22.2 ± 16.18 | -16.2 ± 14.13 | -19.5 ± 15.45 |
| Week 52 (n=30, 22, 52) | -20.6 ± 15.16 | -16.2 ± 15.62 | -18.7 ± 15.36 |
Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported.
| nails | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Baseline | 7.94 ± 2.82 | 7.13 ± 3.07 | 7.55 ± 2.95 |
| Week 8 (n=32, 28, 60) | 7.66 ± 3.17 | 7.11 ± 3.02 | 7.40 ± 3.09 |
| Week 16 (n=32, 28, 60) | 6.91 ± 3.43 | 5.75 ± 3.56 | 6.37 ± 3.51 |
| Week 20 (n=32, 27, 59) | 6.16 ± 3.60 | 4.59 ± 4.02 | 5.44 ± 3.85 |
| Week 28 (n=32, 27, 59) | 4.53 ± 3.87 | 3.59 ± 3.96 | 4.10 ± 3.91 |
| Week 40 (n=31, 26, 57) | 3.32 ± 3.94 | 3.77 ± 3.81 | 3.53 ± 3.85 |
| Week 52 (n=30, 22, 52) | 3.73 ± 4.25 | 2.50 ± 3.07 | 3.21 ± 3.81 |
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Baseline | 6.16 ± 2.669 | 5.32 ± 2.967 | 5.74 ± 2.839 |
| Week 2 | 5.19 ± 2.797 | 3.30 ± 2.530 | 4.23 ± 2.815 |
| Week 4 | 3.65 ± 2.379 | 2.27 ± 2.472 | 2.95 ± 2.510 |
| Week 8 (n=43, 41, 84) | 2.26 ± 2.381 | 1.22 ± 1.739 | 1.75 ± 2.145 |
| Week 12 (n=43, 41, 84) | 1.77 ± 2.379 | 1.20 ± 1.833 | 1.49 ± 2.137 |
| Week 16 (n=43, 40, 83) | 1.67 ± 2.378 | 0.90 ± 1.257 | 1.30 ± 1.949 |
| Week 20 (n=43, 39, 82) | 0.95 ± 1.618 | 1.28 ± 1.589 | 1.11 ± 1.603 |
| Week 28 (n=43, 39, 82) | 1.12 ± 1.651 | 1.62 ± 2.196 | 1.35 ± 1.933 |
| Week 40 (n=41, 38, 79) | 0.90 ± 1.814 | 1.13 ± 1.848 | 1.01 ± 1.822 |
| Week 52 (n=39, 32, 71) | 1.15 ± 2.084 | 0.91 ± 1.329 | 1.04 ± 1.776 |
The DLQI is a 10 item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Baseline | 11.3 ± 6.25 | 8.6 ± 5.91 | 9.9 ± 6.19 |
| Week 2 | 7.8 ± 5.20 | 5.8 ± 5.32 | 6.8 ± 5.32 |
| Week 4 (n=43, 43, 86) | 5.9 ± 5.07 | 4.2 ± 4.63 | 5.1 ± 4.90 |
| Week 8 (n=43, 41, 84) | 4.0 ± 3.95 | 2.8 ± 3.30 | 3.4 ± 3.67 |
| Week 12 (n=43, 41, 84) | 2.6 ± 2.86 | 1.8 ± 2.68 | 2.2 ± 2.79 |
| Week 16 (n=43, 40, 83) | 2.2 ± 3.04 | 1.9 ± 2.73 | 2.1 ± 2.88 |
| Week 20 (n=43, 39, 82) | 1.9 ± 3.13 | 1.8 ± 2.54 | 1.9 ± 2.84 |
| Week 28 (n=43, 39, 82) | 1.7 ± 2.66 | 2.9 ± 3.68 | 2.3 ± 3.23 |
| Week 40 (n=41, 38, 79) | 1.8 ± 2.81 | 2.3 ± 4.11 | 2.0 ± 3.48 |
| Week 52 (n=39, 32, 71) | 1.6 ± 2.42 | 2.2 ± 4.00 | 1.9 ± 3.22 |
36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| W16: Physical Functioning Domain (n=43, 40, 83) | 1.951 ± 5.1880 | 4.809 ± 9.1822 | 3.329 ± 7.4800 |
| W16: Role-Physical Domain (n=43, 40, 83) | 6.160 ± 9.3615 | 5.130 ± 11.1600 | 5.664 ± 10.2172 |
| W16: Bodily Pain Domain (n=43, 40, 83) | 11.808 ± 13.8431 | 10.663 ± 12.2936 | 11.256 ± 13.0524 |
| W16: General Health Domain (n=43, 40, 83) | 2.392 ± 7.0933 | 4.333 ± 7.0145 | 3.328 ± 7.0799 |
| W16: Vitality Domain (n=43, 40, 83) | 4.664 ± 9.5406 | 3.517 ± 11.4421 | 4.112 ± 10.4509 |
| W16: Social Function Domain (n=43, 40, 83) | 7.629 ± 9.9734 | 7.932 ± 8.8645 | 7.775 ± 9.3992 |
| W16: Role-Emotional Domain (n=43, 40, 83) | 7.219 ± 11.5898 | 5.584 ± 11.5654 | 6.431 ± 11.5365 |
| W16: Mental Health Domain (n=43, 40, 83) | 5.928 ± 12.8757 | 5.125 ± 13.3613 | 5.541 ± 13.0378 |
| W28: Physical Functioning Domain (n=43, 39, 82) | 1.571 ± 6.3446 | 4.303 ± 10.3695 | 2.870 ± 8.5558 |
| W28: Role-Physical Domain (n=43, 39, 82) | 5.882 ± 10.6375 | 5.017 ± 11.4671 | 5.471 ± 10.9795 |
| W28: Bodily Pain Domain (n=43, 39, 82) | 10.113 ± 15.9485 | 8.394 ± 12.5405 | 9.295 ± 14.3670 |
| W28: General Health Domain (n=43, 39, 82) | 2.644 ± 5.9230 | 3.517 ± 7.1375 | 3.059 ± 6.5025 |
| W28: Vitality Domain (n=43, 39, 82) | 4.038 ± 10.0116 | 3.608 ± 10.0742 | 3.833 ± 9.9815 |
| W28: Social Function Domain (n=43, 39, 82) | 6.628 ± 11.3068 | 6.205 ± 10.4347 | 6.427 ± 10.8358 |
| W28: Role-Emotional Domain (n=43, 39, 82) | 7.395 ± 11.8846 | 6.310 ± 12.9504 | 6.879 ± 12.3375 |
| W28: Mental Health Domain (n=43, 39, 82) | 6.701 ± 12.4375 | 5.328 ± 12.8129 | 6.048 ± 12.5580 |
| W52: Physical Functioning Domain (n=39,32,71) | 2.151 ± 5.6134 | 3.773 ± 7.3533 | 2.882 ± 6.4585 |
| W52: Role-Physical Domain (n=39, 32, 71) | 6.669 ± 10.0520 | 4.623 ± 9.7340 | 5.747 ± 9.8926 |
| W52: Bodily Pain Domain (n=39, 32, 71) | 12.335 ± 12.1413 | 10.673 ± 9.7128 | 11.586 ± 11.0678 |
| W52: General Health Domain (n=39, 32, 71) | 2.758 ± 6.0866 | 4.888 ± 6.8235 | 3.718 ± 6.4707 |
| W52: Vitality Domain (n=39, 32, 71) | 4.068 ± 10.5612 | 5.052 ± 8.5160 | 4.511 ± 9.6390 |
| W52: Social Function Domain (n=39, 32, 71) | 8.411 ± 9.4598 | 8.402 ± 9.2577 | 8.407 ± 9.3024 |
| W52: Role-Emotional Domain (n=39, 32, 71) | 8.445 ± 11.0018 | 5.915 ± 10.3091 | 7.305 ± 10.6949 |
| W52: Mental Health Domain (n=39, 32, 71) | 7.317 ± 11.6243 | 6.926 ± 12.6861 | 7.141 ± 12.0276 |
36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 16: Physical Health Score (n=43, 40, 83) | 4.719 ± 6.6806 | 6.146 ± 8.5192 | 5.407 ± 7.6087 |
| Week 16: Mental Health Score (n=43, 40, 83) | 6.767 ± 11.0945 | 5.029 ± 11.4967 | 5.929 ± 11.2548 |
| Week 28: Physical Health Score (n=43, 39, 82) | 3.770 ± 7.7829 | 4.799 ± 8.8893 | 4.259 ± 8.2914 |
| Week 28: Mental Health Score (n=43, 39, 82) | 7.085 ± 11.3660 | 5.364 ± 10.9089 | 6.266 ± 11.1159 |
| Week 52: Physical Health Score (n=39, 32, 71) | 4.676 ± 5.7405 | 5.250 ± 5.7614 | 4.935 ± 5.7159 |
| Week 52: Mental Health Score (n=39, 32, 71) | 7.878 ± 10.1983 | 6.826 ± 10.5988 | 7.404 ± 10.3192 |
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5 items); Physical Demands scale (6 items); Mental-Interpersonal Demands Scale (9 items); Output Demands Scale (5 items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| BL: Time Management scale (n=34, 37, 71) | 44.49 ± 37.783 | 42.36 ± 33.716 | 43.38 ± 35.479 |
| BL: Physical Demands scale (n=33, 35, 68) | 66.67 ± 33.522 | 78.40 ± 31.122 | 72.71 ± 32.606 |
| BL: Mental/Interpersonal Demands Scale(n=34,38,72) | 28.61 ± 29.012 | 31.52 ± 30.930 | 30.15 ± 29.865 |
| BL: Output Demands scale (n=33, 37, 70) | 22.61 ± 26.832 | 30.27 ± 35.295 | 26.66 ± 31.602 |
| BL: WLQ Index Score (n=34, 38, 72) | 9.55 ± 6.716 | 10.74 ± 8.045 | 10.18 ± 7.420 |
| W4: Time Management scale (n=31, 36, 67) | 35.32 ± 42.425 | 31.39 ± 36.715 | 33.21 ± 39.203 |
| W4: Physical Demands scale (n=29, 36, 65) | 77.16 ± 33.013 | 83.59 ± 29.593 | 80.72 ± 31.083 |
| W4:Mental/Interpersonal Demands Scale(n=32,36,68) | 17.94 ± 26.979 | 23.39 ± 32.878 | 20.82 ± 30.149 |
| W4: Output Demands scale (n=30, 36, 66) | 13.50 ± 21.978 | 20.14 ± 33.306 | 17.12 ± 28.704 |
| W4: WLQ Index Score (n=32, 37, 69) | 7.23 ± 5.591 | 8.66 ± 7.754 | 8.00 ± 6.827 |
| W16: Time Management scale (n=31, 35, 66) | 35.07 ± 38.894 | 33.29 ± 39.182 | 34.12 ± 38.756 |
| W16: Physical Demands scale (n=30, 32, 62) | 81.60 ± 26.982 | 86.52 ± 25.548 | 84.14 ± 26.153 |
| W16:Mental/Interpersonal Demands Scale(n=31,35,66) | 13.33 ± 21.038 | 20.28 ± 33.419 | 17.01 ± 28.296 |
| W16: Output Demands scale (n=32, 33, 65) | 11.88 ± 20.111 | 19.55 ± 32.485 | 15.77 ± 27.175 |
| W16: WLQ Index Score (n=32, 35, 67) | 6.88 ± 4.715 | 8.35 ± 7.425 | 7.65 ± 6.276 |
| W28: Time Management scale (n=34, 34, 68) | 38.68 ± 40.100 | 29.78 ± 39.092 | 34.23 ± 39.557 |
| W28: Physical Demands scale (n=32, 34, 66) | 76.02 ± 31.041 | 85.42 ± 24.730 | 80.86 ± 28.151 |
| W28:Mental/Interpersonal Demands Scale(n=33,35,68) | 16.84 ± 28.242 | 16.39 ± 27.736 | 16.61 ± 27.774 |
| W28: Output Demands scale (n=33, 34, 67) | 13.94 ± 27.408 | 14.71 ± 28.761 | 14.33 ± 27.892 |
| W28: WLQ Index Score (n=34, 36, 70) | 7.43 ± 6.493 | 7.26 ± 6.829 | 7.34 ± 6.620 |
| W52: Time Management scale (n=31, 31, 62) | 50.32 ± 43.683 | 31.88 ± 40.686 | 41.10 ± 42.883 |
| W52: Physical Demands scale (n=29, 29, 58) | 78.16 ± 30.205 | 89.74 ± 24.410 | 83.95 ± 27.838 |
| W52:Mental/Interpersonal Demands Scale(n=30,30,60) | 25.56 ± 36.007 | 16.89 ± 27.293 | 21.22 ± 31.977 |
| W52: Output Demands scale (n=30, 29, 59) | 22.63 ± 33.750 | 12.24 ± 24.589 | 17.52 ± 29.813 |
| W52: WLQ Index Score (n=32, 31, 63) | 9.44 ± 8.127 | 7.34 ± 6.429 | 8.41 ± 7.358 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Baseline: Clear | 0 | 0 | 0 |
| Baseline: Almost Clear | 0 | 0 | 0 |
| Baseline: Mild | 0 | 2.3 | 1.1 |
| Baseline: Moderate | 41.9 | 43.2 | 42.5 |
| Baseline: Severe | 58.1 | 54.5 | 56.3 |
| Week 2: Clear | 0 | 0 | 0 |
| Week 2: Almost Clear | 2.3 | 0 | 1.1 |
| Week 2: Mild | 2.3 | 29.5 | 16.1 |
| Week 2: Moderate | 60.5 | 36.4 | 48.3 |
| Week 2: Severe | 34.9 | 34.1 | 34.5 |
| Week 4: Clear (n=43, 43, 86) | 0 | 2.3 | 1.2 |
| Week 4: Almost Clear (n=43, 43, 86) | 4.7 | 9.3 | 7.0 |
| Week 4: Mild (n=43, 43, 86) | 18.6 | 25.6 | 22.1 |
| Week 4: Moderate (n=43, 43, 86) | 53.5 | 48.8 | 51.2 |
| Week 4: Severe (n=43, 43, 86) | 23.3 | 14.0 | 18.6 |
| Week 8: Clear (n=43, 41, 84) | 4.7 | 7.3 | 6.0 |
| Week 8: Almost Clear (n=43, 41, 84) | 14.0 | 17.1 | 15.5 |
| Week 8: Mild (n=43, 41, 84) | 32.6 | 34.1 | 33.3 |
| Week 8: Moderate (n=43, 41, 84) | 39.5 | 34.1 | 36.9 |
| Week 8: Severe (n=43, 41, 84) | 9.3 | 7.3 | 8.3 |
| Week 12: Clear (n=43, 41, 84) | 2.3 | 7.3 | 4.8 |
| Week 12: Almost Clear (n=43, 41, 84) | 20.9 | 26.8 | 23.8 |
| Week 12: Mild (n=43, 41, 84) | 34.9 | 41.5 | 38.1 |
| Week 12: Moderate (n=43, 41, 84) | 34.9 | 17.1 | 26.2 |
| Week 12: Severe (n=43, 41, 84) | 7.0 | 7.3 | 7.1 |
| Week 16: Clear (n=43, 40, 83) | 4.7 | 10.0 | 7.2 |
| Week 16: Almost Clear (n=43, 40, 83) | 32.6 | 22.5 | 27.7 |
| Week 16: Mild (n=43, 40, 83) | 23.3 | 35.0 | 28.9 |
| Week 16: Moderate (n=43, 40, 83) | 32.6 | 22.5 | 27.7 |
| Week 16: Severe (n=43, 40, 83) | 7.0 | 10.0 | 8.4 |
| Week 20: Clear (n=43, 39, 82) | 7.0 | 12.8 | 9.8 |
| Week 20: Almost Clear (n=43, 39, 82) | 37.2 | 23.1 | 30.5 |
| Week 20: Mild (n=43, 39, 82) | 25.6 | 33.3 | 29.3 |
| Week 20: Moderate (n=43, 39, 82) | 23.3 | 25.6 | 24.4 |
| Week 20: Severe (n=43, 39, 82) | 7.0 | 5.1 | 6.1 |
| Week 28: Clear (n=43, 39, 82) | 11.6 | 5.1 | 8.5 |
| Week 28: Almost Clear (n=43, 39, 82) | 37.2 | 35.9 | 36.6 |
| Week 28: Mild (n=43, 39, 82) | 23.3 | 20.5 | 22.0 |
| Week 28: Moderate (n=43, 39, 82) | 20.9 | 33.3 | 26.8 |
| Week 28: Severe (n=43, 39, 82) | 7.0 | 5.1 | 6.1 |
| Week 40: Clear (n=41, 38, 79) | 7.3 | 18.4 | 12.7 |
| Week 40: Almost Clear (n=41, 38, 79) | 46.3 | 31.6 | 39.2 |
| Week 40: Mild (n=41, 38, 79) | 19.5 | 18.4 | 19.0 |
| Week 40: Moderate (n=41, 38, 79) | 22.0 | 26.3 | 24.1 |
| Week 40: Severe (n=41, 38, 79) | 4.9 | 5.3 | 5.1 |
| Week 52: Clear (n=39, 32, 71) | 20.5 | 18.8 | 19.7 |
| Week 52: Almost Clear (n=39, 32, 71) | 20.5 | 31.3 | 25.4 |
| Week 52: Mild (n=39, 32, 71) | 28.2 | 25.0 | 26.8 |
| Week 52: Moderate (n=39, 32, 71) | 15.4 | 21.9 | 18.3 |
| Week 52: Severe (n=39, 32, 71) | 15.4 | 3.1 | 9.9 |
The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to "select the number that best describes any joint pain that participant may have experienced over the past 24 hours" with response options ranging from "0-no joint pain" to "10-worst possible joint pain."
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Baseline | 5.25 ± 3.327 | 4.60 ± 2.558 | 4.83 ± 2.790 |
| Week 4 (n=8, 14, 22) | 4.00 ± 2.726 | 1.36 ± 1.008 | 2.32 ± 2.191 |
| Week 16 (n=8, 15, 23) | 1.88 ± 2.295 | 0.60 ± 0.737 | 1.04 ± 1.551 |
| Week 28 (n=8, 14, 22) | 1.75 ± 1.753 | 0.86 ± 0.949 | 1.18 ± 1.332 |
| Week 52 (n=4, 13, 17) | 0.50 ± 0.577 | 0.54 ± 0.660 | 0.53 ± 0.624 |
ACR20 response: greater than or equal to (\>=) 20 percent (%) improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 0.0 | 62.5 | 41.7 |
| Week 4 | 50.0 | 75.0 | 66.7 |
| Week 8 | 75.0 | 100 | 91.7 |
| Week 12 | 100 | 87.5 | 91.7 |
| Week 20 | 100 | 87.5 | 91.7 |
| Week 28 | 100 | 100 | 100 |
| Week 40 | 75.0 | 100 | 91.7 |
| Week 52 | 50.0 | 100 | 83.3 |
ACR50 response: greater than or equal to (\>=) 50 percent (%) improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 0.0 | 25.0 | 16.7 |
| Week 4 | 25.0 | 50.0 | 41.7 |
| Week 8 | 50.0 | 62.5 | 58.3 |
| Week 12 | 75.0 | 75.0 | 75.0 |
| Week 16 | 75.0 | 87.5 | 83.3 |
| Week 20 | 100 | 87.5 | 91.7 |
| Week 28 | 100 | 75.0 | 83.3 |
| Week 40 | 75.0 | 87.5 | 83.3 |
| Week 52 | 50.0 | 87.5 | 75.0 |
ACR70 response: greater than or equal to (\>=) 70 percent (%) improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
| Percentage of participants | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | 0.0 | 0.0 | 0.0 |
| Week 4 | 0.0 | 37.5 | 25.0 |
| Week 8 | 25.0 | 62.5 | 50.0 |
| Week 12 | 50.0 | 62.5 | 58.3 |
| Week 16 | 50.0 | 62.5 | 58.3 |
| Week 20 | 75.0 | 75.0 | 75.0 |
| Week 28 | 75.0 | 50.0 | 58.3 |
| Week 40 | 50.0 | 75.0 | 66.7 |
| Week 52 | 50.0 | 75.0 | 66.7 |
Sixty eight (68) joints were assessed by a rheumatologist investigator to determine the number of joints that were considered tender or painful. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).
| Tender/painful joints | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -1.8 ± 1.50 | -3.5 ± 2.78 | -2.9 ± 2.50 |
| Week 4 | -6.3 ± 6.70 | -9.3 ± 11.37 | -8.3 ± 9.84 |
| Week 8 | -11.5 ± 10.08 | -11.6 ± 10.24 | -11.6 ± 9.72 |
| Week 12 | -13.8 ± 10.78 | -12.5 ± 11.95 | -12.9 ± 11.09 |
| Week 16 | -13.0 ± 9.59 | -13.0 ± 12.17 | -13.0 ± 10.92 |
| Week 20 | -14.3 ± 9.11 | -12.4 ± 12.87 | -13.0 ± 11.35 |
| Week 28 | -14.0 ± 9.38 | -12.4 ± 12.52 | -12.9 ± 11.16 |
| Week 40 | -14.3 ± 10.14 | -13.4 ± 12.09 | -13.7 ± 11.02 |
| Week 52 (n=3, 8, 11) | -11.3 ± 9.24 | -13.5 ± 12.08 | -12.9 ± 10.97 |
Sixty six (66) joints were assessed for swelling by a rheumatologist investigator to determine the number of joints that were considered swelling. The response to pressure/motion on each joint was assessed with the following scale: Present/Absent/Not Done/Not Applicable (for Artificial or missing joints).
| Swollen joints | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -1.8 ± 2.22 | -3.8 ± 5.55 | -3.1 ± 4.68 |
| Week 4 | -5.0 ± 4.69 | -5.3 ± 5.80 | -5.2 ± 5.24 |
| Week 8 | -6.0 ± 7.35 | -6.4 ± 4.37 | -6.3 ± 5.19 |
| Week 12 | -6.5 ± 6.35 | -7.0 ± 4.44 | -6.8 ± 4.86 |
| Week 16 | -7.3 ± 7.85 | -7.8 ± 3.85 | -7.6 ± 5.12 |
| Week 20 | -7.0 ± 8.00 | -8.9 ± 4.42 | -8.3 ± 5.55 |
| Week 28 | -7.3 ± 7.85 | -7.6 ± 4.03 | -7.5 ± 5.21 |
| Week 40 | -7.3 ± 7.85 | -8.8 ± 4.20 | -8.3 ± 5.34 |
| Week 52 (n=3, 8, 11) | -3.0 ± 0.00 | -8.8 ± 4.13 | -7.2 ± 4.38 |
Subjects assessed the severity of their arthritis pain with a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (the most severe pain), which corresponded to the magnitude of their pain.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -13.3 ± 8.30 | -29.5 ± 23.40 | -24.1 ± 20.77 |
| Week 4 | -13.0 ± 23.41 | -41.4 ± 25.29 | -31.9 ± 27.42 |
| Week 8 | -16.0 ± 19.78 | -43.6 ± 22.68 | -34.4 ± 24.88 |
| Week 12 | -34.5 ± 19.71 | -46.0 ± 23.42 | -42.2 ± 22.07 |
| Week 16 | -27.3 ± 15.22 | -46.0 ± 22.44 | -39.8 ± 21.65 |
| Week 20 | -44.0 ± 22.82 | -45.3 ± 21.53 | -44.8 ± 20.91 |
| Week 28 | -45.8 ± 23.26 | -45.8 ± 20.46 | -45.8 ± 20.34 |
| Week 40 | -20.0 ± 54.86 | -46.9 ± 22.66 | -37.9 ± 36.37 |
| Week 52 (n=3, 8, 11) | -33.0 ± 31.19 | -48.4 ± 22.14 | -44.2 ± 24.28 |
Subjects answered the following question, "Considering the possible effects of the arthritis, how are you feeling today?" The subject's response was recorded with a 100 mm visual analog scale (VAS), where 0 = very well and 100 = very poorly.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -8.0 ± 8.87 | -32.6 ± 27.55 | -24.4 ± 25.53 |
| Week 4 | -20.5 ± 11.27 | -43.4 ± 27.47 | -35.8 ± 25.33 |
| Week 8 | -23.3 ± 19.69 | -51.3 ± 20.53 | -41.9 ± 23.75 |
| Week 12 | -45.0 ± 8.83 | -52.1 ± 21.35 | -49.8 ± 17.99 |
| Week 16 | -40.0 ± 13.64 | -53.0 ± 20.96 | -48.7 ± 19.27 |
| Week 20 | -49.5 ± 20.09 | -49.6 ± 20.26 | -49.6 ± 19.27 |
| Week 28 | -52.3 ± 11.18 | -46.3 ± 26.67 | -48.3 ± 22.26 |
| Week 40 | -20.8 ± 30.24 | -50.8 ± 20.78 | -40.8 ± 27.24 |
| Week 52 (n=3, 8, 11) | -40.7 ± 16.80 | -55.3 ± 20.51 | -51.3 ± 19.94 |
The rheumatologist investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease signs, functional capacity and physical examination, and was independent of the PGA of arthritis. The rheumatologist investigator's response was recorded a 100 mm visual analog scale (VAS), where 0 = very good and 100 = very poor.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -15.3 ± 18.01 | -28.5 ± 18.60 | -24.1 ± 18.74 |
| Week 4 | -32.5 ± 22.28 | -34.6 ± 19.39 | -33.9 ± 19.38 |
| Week 8 | -29.5 ± 30.01 | -41.8 ± 21.87 | -37.7 ± 24.21 |
| Week 12 | -39.8 ± 21.00 | -45.8 ± 22.76 | -43.8 ± 21.42 |
| Week 16 | -49.8 ± 23.34 | -47.9 ± 20.09 | -48.5 ± 20.16 |
| Week 20 | -50.8 ± 25.29 | -45.3 ± 26.81 | -47.1 ± 25.28 |
| Week 28 | -49.5 ± 25.96 | -42.8 ± 22.79 | -45.0 ± 22.92 |
| Week 40 | -38.5 ± 39.03 | -49.5 ± 18.54 | -45.8 ± 25.76 |
| Week 52 (n=3, 8, 11) | -29.0 ± 20.30 | -46.8 ± 25.08 | -41.9 ± 24.32 |
The blood samples were collected at each visit for analysis of CRP with an assay analyzed by the central laboratory.
| mg/dL | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -1.20 ± 2.137 | -1.68 ± 2.231 | -1.52 ± 2.114 |
| Week 4 | -1.20 ± 2.267 | -1.69 ± 2.272 | -1.53 ± 2.178 |
| Week 8 | -1.28 ± 2.354 | -1.70 ± 2.222 | -1.56 ± 2.167 |
| Week 12 | -1.28 ± 2.351 | -1.68 ± 2.235 | -1.54 ± 2.174 |
| Week 16 | -1.30 ± 2.337 | -1.69 ± 2.189 | -1.56 ± 2.139 |
| Week 20 | -1.33 ± 2.387 | -1.59 ± 2.336 | -1.50 ± 2.246 |
| Week 28 | -1.30 ± 2.337 | -1.15 ± 2.770 | -1.20 ± 2.526 |
| Week 40 (n=4, 7, 11) | -1.15 ± 2.037 | -1.84 ± 2.461 | -1.59 ± 2.236 |
| Week 52 (n=3, 8, 11) | -0.03 ± 0.058 | -1.65 ± 2.295 | -1.21 ± 2.064 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.
| Units on a scale | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Week 2 | -0.19 ± 0.239 | -0.28 ± 0.376 | -0.25 ± 0.329 |
| Week 4 | -0.28 ± 0.329 | -0.36 ± 0.381 | -0.33 ± 0.351 |
| Week 8 | -0.28 ± 0.359 | -0.42 ± 0.433 | -0.38 ± 0.399 |
| Week 12 | -0.28 ± 0.359 | -0.42 ± 0.433 | -0.38 ± 0.399 |
| Week 16 | -0.31 ± 0.375 | -0.42 ± 0.433 | -0.39 ± 0.400 |
| Week 20 | -0.28 ± 0.359 | -0.42 ± 0.433 | -0.38 ± 0.399 |
| Week 28 | -0.34 ± 0.400 | -0.42 ± 0.433 | -0.40 ± 0.405 |
| Week 40 | -0.09 ± 0.640 | -0.42 ± 0.433 | -0.31 ± 0.507 |
| Week 52 (n=3, 8, 11) | -0.13 ± 0.573 | -0.42 ± 0.433 | -0.34 ± 0.465 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 5 mg BID | — | 3/47 (6.4%) | 37/47 (78.7%) |
| CP-690,550 10 mg BID | — | 3/47 (6.4%) | 40/47 (85.1%) |
| Total | — | 6/94 (6.4%) | 77/94 (81.9%) |
| Event | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Herpes zosterInfections and infestations | 3/47 | 0/47 | 3/94 |
| VertigoEar and labyrinth disorders | 0/47 | 1/47 | 1/94 |
| ImpetigoInfections and infestations | 0/47 | 1/47 | 1/94 |
| Erythrodermic psoriasisSkin and subcutaneous tissue disorders | 0/47 | 1/47 | 1/94 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/47 | 1/47 | 1/94 |
| Event | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 14/47 | 14/47 | 28/94 |
| Herpes zosterInfections and infestations | 3/47 | 10/47 | 13/94 |
| Tinea pedisInfections and infestations | 4/47 | 6/47 | 10/94 |
| PsoriasisSkin and subcutaneous tissue disorders | 4/47 | 6/47 | 10/94 |
| Haemoglobin decreasedInvestigations | 1/47 | 4/47 | 5/94 |
| Dental cariesGastrointestinal disorders | 3/47 | 1/47 | 4/94 |
| PyrexiaGeneral disorders | 0/47 | 3/47 | 3/94 |
| GastroenteritisInfections and infestations | 3/47 | 0/47 | 3/94 |
| InfluenzaInfections and infestations | 3/47 | 3/47 | 6/94 |
| Alanine aminotransferase increasedInvestigations | 1/47 | 3/47 | 4/94 |
| Age, Continuous(years) | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Mean | 50.9 ± 11.8 | 46.4 ± 10.8 | 48.7 ± 11.5 |
| Sex: Female, Male(Participants) | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 39 | 39 | 78 |
The record gives a start of Mar 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib